Retina Clinical Trial
Official title:
Extension of Protocol 002, Carbidopa-levodopa in Neovascular Extension of Protocol 002, Carbidopa-levodopa in Neovascular AMD
NCT number | NCT03197493 |
Other study ID # | 0003 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | August 1, 2017 |
Est. completion date | July 9, 2020 |
Verified date | December 2020 |
Source | Snyder, Robert W., M.D., Ph.D., P.C. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This protocol is an extension of protocol 0002, Proof of Concept and Dose Ranging Study of carbidopa-levodopa in Neovascular AMD. that is a 3 month study of escalating doses of carbidopa-levodopa in neovascular AMD. This trial is a 9 month extension for patients who successfully complete protocol 0002 and wish to continue carbidopa-levodopa therapy. It will use the two higher dose regimens of protocol 0002. these will be assigned according to how well the higher dose was tolerated in protocol 0002.
Status | Completed |
Enrollment | 32 |
Est. completion date | July 9, 2020 |
Est. primary completion date | July 9, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Completion of Protocol 002. 2. A diagnosis of AMd with choroidal neovascularization (CNV) in 1 eye. 3. Normal or Dry AMD of any grade in the second eye. 4. Age 50-85 years. 5. Willingness to maintain AREDS vitamin Supplements throughout the study, or remain off of these supplements for the duration of the study, if not taking them prior to the study. 6. Informed consent at visit 1, which is also Visit 5 of study 002. Exclusion criteria: 1. Any current use of L-DOPA containing medication or dopamine agonist medication, or any planned use of any of these agents, except for study medication, during the study; 2. Concurrent use of monoamine oxidase (MAO) inhibitors; 3. Any eye condition, disease, or history of trauma in either eye, which can impair vision, except cataract or cataract surgery; 4. BCVA worse than 20/60 in the better eye; 5. Wet AMD in the second eye; 6. Neurologic conditions which can impair vision; 7. Parkinson's Disease; 8. Significant orthostatic hypotension, defined as a drop in systolic blood pressure, immediately upon changing from the supine to standing position, of >19 mmHg, or a symptomatic drop in systolic blood pressure, immediately upon changing from the supine to standing position; 9. Significant ECG abnormalities, as judged by the Investigator; 10. Estimated glomerular filtration rate (eGFR) <20 ml/min; 11. Liver enzymes >3 X the upper limit of normal; 12. HbA1C >9.0; 13. Any other significant lab abnormalities, as judged by the Investigator. 14. Women of childbearing potential; 15. Known retinal hemorrhage; 16. Subjects who are not fluent in English. |
Country | Name | City | State |
---|---|---|---|
United States | Robert W Snyder, MD, PhD, PC | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
Snyder, Robert W., M.D., Ph.D., P.C. | Snyder Biomedical Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Best Corrected Visual Acuity by ETDRS visual scale testing | Currently refracted, normal light, lines and letters read on the ETDRS chart | From the start of the study (Visit 1) to the last completed visit, whether due to patient withdrawal, patient death or the completion of the last visit of the study (visit 10), a maximum of 9 months. | |
Secondary | Number of adverse events experienced by participants during the study | Adverse events elicited by nonspecific questioning | Monthly for 9 months | |
Secondary | By OCT, central retinal thickness, in the eye with neovascular AMD | Central retinal thickness by OCT | From the start of the study (Visit 1) to the last completed visit, whether due to patient withdrawal, patient death or the completion of the last visit of the study (visit 10), a maximum of 9 months. | |
Secondary | By OCT, drusen volume in the eye without neovascular AMD | drusen volume | From the start of the study (Visit 1) to the last completed visit, whether due to patient withdrawal, patient death or the completion of the last visit of the study, (visit 10), a maximum of 9 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00431691 -
Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans.
|
Phase 4 | |
Completed |
NCT01157338 -
Clinical Significance of Retinal Emboli During Diagnostic and Therapeutic Cardiac Catheterization
|
N/A | |
Completed |
NCT03326908 -
Description of the Interdigitation Retinal Area by SD-OCT: An Exploratory Study
|
N/A | |
Completed |
NCT04794634 -
Relationship Between Alzheimer Disease and Diminution of the Three Macular Nervous Retinal Layers
|
N/A | |
Recruiting |
NCT05747742 -
Effect of Different Intensities of Repeated Low-Level Red-Light Therapy on Choroidal and Retinal Blood Flow Among Adults
|
N/A | |
Completed |
NCT00709423 -
Effects of Moxaverine and Placebo on Ocular Blood Flow
|
Phase 2 | |
Completed |
NCT00814008 -
The Relationship Between Stage of Diabetic Retinopathy and Retinal Blood Flow in Patients With IDDM During Euglycemic Clamp
|
Phase 2 | |
Terminated |
NCT04408677 -
Normative Data Collection Study of the Zilia Ocular for the Measurement of Oxygen Saturation in the Retina
|
N/A | |
Completed |
NCT00451763 -
Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia
|
Phase 3 | |
Completed |
NCT00706927 -
Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
|
N/A | |
Recruiting |
NCT02614625 -
Spectral-domain Optical Coherence Tomography of the Eye
|
N/A | |
Completed |
NCT00431730 -
Is There a Difference in Flicker Induced Vasodilatation Between Smokers and Non-Smokers?
|
N/A | |
Not yet recruiting |
NCT05796856 -
Effect of Different Wavelengths of Repeated Low-Level Light Therapy on Choroidal and Retinal Blood Flow Among Adults
|
N/A | |
Completed |
NCT00431548 -
Retinal Oxygen Reactivity in Patients Infected With Human Immunodeficiency Virus (HIV)
|
N/A |